Login to Your Account

Financings Roundup

Agios Scores $78M to Advance Its Cancer Metabolism Work

By Marie Powers
Staff Writer

Friday, November 18, 2011
Agios Pharmaceuticals bagged $78 million in an oversubscribed Series C, signaling that the financing gate – if not floodgate – remains open for emerging biotechs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription